

## **Presidio Pharmaceuticals, Inc. to Present Data on their lead Hepatitis C Virus NS5A Inhibitor Program at the European Association for the Study of the Liver (EASL) Conference**

**San Francisco, CA – April 16, 2009** – Presidio Pharmaceuticals, Inc. announced today that Dr. Richard Colonno, the company's Chief Scientific Officer, would be presenting data on their hepatitis C virus NS5A inhibitor program at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark (April 22-26, 2009). Dr. Colonno will be presenting new data on several series of potent NS5A inhibitors in a poster entitled **Identification and Profile of Potent and Selective Inhibitors of HCV NS5A Protein** - Poster #875, Saturday April 25, 2009.

The full abstract is now available for viewing on [www.easl.ch](http://www.easl.ch).

### **About Presidio Pharmaceuticals, Inc.**

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV-1. Presidio has raised over \$27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus Medical Partners, and Sagamore Bioventures LLC. For more information, please visit our website at [www.presidiopharma.com](http://www.presidiopharma.com).

### **Contact:**

Omar K. Haffar, Ph.D.  
President and Chief Executive Officer  
[omar@presidiopharma.com](mailto:omar@presidiopharma.com)  
415-655-7561